Marshall Wace LLP Lowers Position in Alector, Inc. (NASDAQ:ALEC)

Marshall Wace LLP reduced its stake in Alector, Inc. (NASDAQ:ALEC - Free Report) by 70.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,609 shares of the company's stock after selling 124,669 shares during the period. Marshall Wace LLP owned 0.05% of Alector worth $239,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Alector by 12.0% in the 1st quarter. Vanguard Group Inc. now owns 4,912,578 shares of the company's stock worth $29,574,000 after acquiring an additional 526,037 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Alector by 16.2% during the first quarter. Jacobs Levy Equity Management Inc. now owns 922,799 shares of the company's stock valued at $5,555,000 after purchasing an additional 128,515 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Alector by 32.8% during the second quarter. Acadian Asset Management LLC now owns 590,662 shares of the company's stock valued at $2,681,000 after purchasing an additional 146,015 shares during the last quarter. Panagora Asset Management Inc. boosted its position in shares of Alector by 61.7% in the 2nd quarter. Panagora Asset Management Inc. now owns 355,318 shares of the company's stock worth $1,613,000 after purchasing an additional 135,614 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Alector by 21.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 279,938 shares of the company's stock worth $1,271,000 after buying an additional 49,625 shares during the last quarter. 85.83% of the stock is owned by institutional investors.

Alector Stock Up 5.5 %

Shares of Alector stock traded up $0.25 on Friday, reaching $4.80. The company's stock had a trading volume of 345,720 shares, compared to its average volume of 625,378. Alector, Inc. has a 52 week low of $3.66 and a 52 week high of $8.90. The firm's fifty day simple moving average is $5.11 and its two-hundred day simple moving average is $5.22. The company has a market capitalization of $467.14 million, a price-to-earnings ratio of -2.67 and a beta of 0.68.

Alector (NASDAQ:ALEC - Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.09. The business had revenue of $15.08 million during the quarter, compared to analyst estimates of $16.04 million. Alector had a negative return on equity of 102.63% and a negative net margin of 290.66%. During the same quarter in the previous year, the firm earned $0.02 EPS. As a group, research analysts predict that Alector, Inc. will post -1.92 EPS for the current year.

Insider Activity at Alector

In other Alector news, CEO Arnon Rosenthal sold 26,499 shares of Alector stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $129,315.12. Following the completion of the sale, the chief executive officer now owns 1,948,746 shares of the company's stock, valued at approximately $9,509,880.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Alector news, CEO Arnon Rosenthal sold 26,499 shares of the firm's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total value of $129,315.12. Following the transaction, the chief executive officer now directly owns 1,948,746 shares of the company's stock, valued at approximately $9,509,880.48. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sara Kenkare-Mitra sold 13,926 shares of the business's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $67,958.88. Following the sale, the insider now owns 291,715 shares of the company's stock, valued at approximately $1,423,569.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 58,222 shares of company stock worth $286,013 over the last quarter. Company insiders own 9.10% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on ALEC. HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Alector in a report on Thursday, June 20th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Alector in a research note on Tuesday, September 17th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Alector currently has an average rating of "Buy" and a consensus target price of $17.75.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.